Protalix BioTherapeutics Inc. (PLX) has sought accelerated approval of Pegunigalsidase alfa (PRX–102) for the proposed treatment of adult patients with Fabry disease, and a decision is expected on April 27, 2021.Fabry disease is an inherited disorder that results from the buildup of a particular type of fat, called globotriaosylceramide, in the body's cells due to deficiency of the enzyme, alpha-galactosidase A (AGA).Enzyme replacement therapies like Sanofi’s Fabrazyme and Amicus’ Galafold are approved in the U.S. for the treatment of Fabry disease.Proyalix’s Pegunigalsidase alfa, which is also an enzyme replacement therapy, is a chemically modified version of recombinant alpha-Galactosidase-A protein, administered as an infusion directly into the bloodstream. Pegunigalsidase alfa is manufactured using the company’s ProCellEx plant cell-based protein expression platform.If approved, Pegunigalsidase alfa could achieve peak sales of $39 million by 2026, according to GlobalData.PLX closed Friday’s (Mar.26, 2021) trading at $4.83, up 0.84%.